Related Experiment Video
Updated: Jul 6, 2025
siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells
Songbin Wu1, Sashuang Wang2, Xiaomian Lin3
1Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, National Key Clinic of Pain Medicine, Shenzhen Nanshan People's Hospital, and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen 518060, China.
Lanatoside C (LanC) effectively inhibits Herpes simplex virus type 1 (HSV-1) replication in cells and mice. This antiviral action is linked to LanC’s ability to trigger NRF2 translocation, suggesting its potential for treating viral infections.
Area of Science:
- Virology
- Pharmacology
- Molecular Biology
Background:
- Herpes simplex virus type 1 (HSV-1) infections pose challenges due to drug-resistant strains.
- Novel antiviral agents with new mechanisms of action are needed.
- Lanatoside C (LanC), an FDA-approved cardiac glycoside, shows potential anticancer and antiviral properties, but its efficacy against HSV-1 is unexplored.
Purpose of the Study:
- To investigate the antiviral activity of LanC against HSV-1.
- To elucidate the molecular mechanisms underlying LanC's anti-HSV-1 effects.
Main Methods:
- In vitro assessment of LanC's antiviral activity in HSV-1 infected ARPE-19 and Vero cells by measuring viral gene and protein levels and virus titers.
- Immunofluorescence (IF) analysis to track intracellular NRF2 distribution.
- In vivo evaluation of LanC's antiviral efficacy in a mouse model of HSV-1 infection, assessing IENFs loss and viral gene inhibition.
Main Results:
- LanC demonstrated significant inhibition of HSV-1 replication both in vitro and in vivo.
- The antiviral mechanism of LanC involves the perinuclear translocation of NRF2.
Conclusions:
- LanC exhibits anti-HSV-1 effects mediated by NRF2 intracellular translocation.
- LanC shows promise as a novel NRF2 modulator for treating viral diseases.
